Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer

Summary

In this study a mistletoe preparation (Iscador Qu) is added to standard therapy in inoperable pancreatic cancer in order to evaluate effect on overall survival and health-related quality of life. Half of participants will take subcutaneous injections with mistletoe in addition to standard therapy (palliative chemotherapy or best supportive care); the other half will receive a placebo and standard therapy.

Conditions

• Pancreatic Cancer

Interventions

DRUG

Mistletoe extract (Iscador Qu)

1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg

DRUG

Placebo

1ml subcutaneous injection 3 times/week

Sponsors & Collaborators

• University of Witten/Herdecke

  collaborator OTHER

• Karolinska Institutet

  collaborator OTHER

• Regional Cancer Centre Stockholm Gotland

  collaborator OTHER

• Stiftelsen Konung Gustaf V:s Jubileumsfond för cancerforskning

  collaborator UNKNOWN

• Signe & Ane Gyllenbergs Stiftelse

  collaborator UNKNOWN

• Ekhagastiftelsen

  collaborator OTHER

• Dagmar Ferbs Minnesfond

  collaborator UNKNOWN

• Cancerforskningsfonden i Norrland

  collaborator UNKNOWN

• Immunpathologisches Labor, University Tübingen

  collaborator UNKNOWN

• The Sjöberg Foundation

  collaborator UNKNOWN

• Karolinska University Hospital

  lead OTHER

Principal Investigators

• Annika Bergquist, Ass Prof · Gastrocentrum Karolinska University Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-06-30

Primary Completion

2022-09-30

Completion

2022-09-30

Countries

• Sweden

Study Locations